Eric W. Thomas

Array ( [id] => 10614876 [patent_doc_number] => 09334310 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-05-10 [patent_title] => 'HIV-1 V3 mimotopes capable of inducing cross-clade neutralizing antibodies' [patent_app_type] => utility [patent_app_number] => 13/914252 [patent_app_country] => US [patent_app_date] => 2013-06-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 9 [patent_no_of_words] => 27460 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13914252 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10267145 [patent_doc_number] => 20150152140 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-04 [patent_title] => 'PEPTIDES DERIVED FROM VIRAL PROTEINS FOR USE AS IMMUNOGENS AND DOSAGE REACTANTS' [patent_app_type] => utility [patent_app_number] => 14/406016 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 38845 [patent_no_of_claims] => 101 [patent_no_of_ind_claims] => 78 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14406016 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10289237 [patent_doc_number] => 20150174235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-06-25 [patent_title] => 'VACCINE' [patent_app_type] => utility [patent_app_number] => 14/405093 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30202 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 35 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405093 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10247259 [patent_doc_number] => 20150132255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-05-14 [patent_title] => 'HIV VACCINE' [patent_app_type] => utility [patent_app_number] => 14/405302 [patent_app_country] => US [patent_app_date] => 2013-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 36740 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 21 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14405302 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14980675 [patent_doc_number] => 10444245 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-15 [patent_title] => Trapping mammalian protein-protein complexes in virus-like particles utilizing HIV-1 GAG-bait fusion proteins [patent_app_type] => utility [patent_app_number] => 14/402667 [patent_app_country] => US [patent_app_date] => 2013-05-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 7 [patent_no_of_words] => 9868 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14402667 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9330571 [patent_doc_number] => 20140057354 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-02-27 [patent_title] => 'ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION' [patent_app_type] => utility [patent_app_number] => 13/898565 [patent_app_country] => US [patent_app_date] => 2013-05-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 11860 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13898565 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9989436 [patent_doc_number] => 09034638 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-19 [patent_title] => 'Arrayed detector system for measurement of anti-viral immune response' [patent_app_type] => utility [patent_app_number] => 13/898143 [patent_app_country] => US [patent_app_date] => 2013-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 9 [patent_no_of_words] => 9334 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 138 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13898143 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9586728 [patent_doc_number] => RE045016 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2014-07-15 [patent_title] => 'Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses' [patent_app_type] => reissue [patent_app_number] => 13/896396 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 47499 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896396 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9619053 [patent_doc_number] => RE045053 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2014-07-29 [patent_title] => 'Attenuated dengue virus comprising mutations in the NS3 gene' [patent_app_type] => reissue [patent_app_number] => 13/896411 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 53209 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 56 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896411 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9701404 [patent_doc_number] => RE045123 [patent_country] => US [patent_kind] => E1 [patent_issue_date] => 2014-09-09 [patent_title] => 'Recombinant attenuated dengue viruses comprising a deletion in the 3′ untranslated region and additional attenuating mutations induced by chemical mutagenesis' [patent_app_type] => reissue [patent_app_number] => 13/896409 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 14 [patent_no_of_words] => 47071 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13896409 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11283745 [patent_doc_number] => 09499589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-11-22 [patent_title] => 'Chimeric vaccines' [patent_app_type] => utility [patent_app_number] => 13/897319 [patent_app_country] => US [patent_app_date] => 2013-05-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 26 [patent_no_of_words] => 29334 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 54 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13897319 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9864119 [patent_doc_number] => 20150044137 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-02-12 [patent_title] => 'NEUTRALIZING ANTIBODIES TO HIV-1 AND THEIR USE' [patent_app_type] => utility [patent_app_number] => 14/386920 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 35961 [patent_no_of_claims] => 46 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386920 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12043466 [patent_doc_number] => 09821050 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-11-21 [patent_title] => 'Chimeric dengue virus E glycoproteins comprising mutant domain I and domain II hinge regions' [patent_app_type] => utility [patent_app_number] => 14/390312 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 11 [patent_no_of_words] => 20482 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14390312 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9916750 [patent_doc_number] => 20150071954 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2015-03-12 [patent_title] => 'STABLE PEPTIDE MIMETICS OF THE HIV-1 GP41 PRE-HAIRPIN INTERMEDIATE' [patent_app_type] => utility [patent_app_number] => 14/386514 [patent_app_country] => US [patent_app_date] => 2013-03-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 24329 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14386514 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9054012 [patent_doc_number] => 20130251726 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-09-26 [patent_title] => 'NOVEL HIV -1 BROADLY NEUTRALIZING ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/792098 [patent_app_country] => US [patent_app_date] => 2013-03-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 49 [patent_figures_cnt] => 49 [patent_no_of_words] => 35566 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13792098 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11237503 [patent_doc_number] => 09464131 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-10-11 [patent_title] => 'Broadly neutralizing human immunodeficiency virus type 1 (HIV-1) GP120-specific monoclonal antibody' [patent_app_type] => utility [patent_app_number] => 13/780776 [patent_app_country] => US [patent_app_date] => 2013-02-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 63 [patent_figures_cnt] => 65 [patent_no_of_words] => 122151 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 37 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13780776 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10522692 [patent_doc_number] => 09249191 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-02-02 [patent_title] => 'Virus like particle composition' [patent_app_type] => utility [patent_app_number] => 13/768801 [patent_app_country] => US [patent_app_date] => 2013-02-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 11282 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 109 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13768801 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10109212 [patent_doc_number] => 09144605 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-09-29 [patent_title] => 'Recombinant rift valley fever virus encoding a dominant-negative inhibitor of DSRNA-dependent protein kinase in the NSS region' [patent_app_type] => utility [patent_app_number] => 13/766941 [patent_app_country] => US [patent_app_date] => 2013-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 9 [patent_no_of_words] => 13214 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13766941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12172233 [patent_doc_number] => 09890361 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-02-13 [patent_title] => 'Methods for increasing the infectivity of viruses utilizing alkyne-modified fatty acids' [patent_app_type] => utility [patent_app_number] => 14/374404 [patent_app_country] => US [patent_app_date] => 2013-01-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14183 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14374404 [rel_patent_id] =>[rel_patent_doc_number] =>)